Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two hormone therapy drugs used in the treatment of hormone receptor-positive breast cancer. Tamoxifen is a selective estrogen receptor modulator (SERM) that works by blocking estrogen receptors, preventing estrogen from stimulating cancer cell growth. Letrozole is an aromatase inhibitor that reduces the amount of estrogen produced in the body by blocking the enzyme aromatase. The BIG 1-98 trial was a significant study that compared these drugs as monotherapy and in sequential treatment approaches. Research has shown that letrozole monotherapy generally provides better outcomes than tamoxifen alone or the combination of both drugs administered simultaneously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tamoxifen + letrozole.